Prevention of gastrointestinal cancer - The potential role of NSAIDs in colorectal cancer

Schweizerische Medizinische Wochenschrift

Volumn 126, Issue 19, 1996, Pages 801-812

  Luk, G D ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ALCOHOL CONSUMPTION; CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; DIET; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; DRUG EFFICACY; HUMAN; LIFESTYLE; SMOKING;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; EPIDEMIOLOGIC METHODS; GASTROINTESTINAL NEOPLASMS; HUMANS; SULINDAC;

EID: 0030013660     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (125)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8.
2. Luk GD: Colorectal cancer. In: Harvey AM, Johns RJ, McKusick VA, Owens AH, Ross RS (eds): The principles and practice of medicine. Norwalk, Connecticut: Appleton and Lange, 1988; 449-455.
3. Luk GD: Colorectal cancer. Gastroenterol Clin North Am 1988; 17: 655-967.
4. Luk GD: Colorectal cancer screening. In: Bayless TM (ed): Current therapy in gastroenterology and liver disease - 3. Philadelphia: B.C. Decker, 1990: 387-391.
5. Luk GD: Colonic polyps: benign and premalignant neoplasma of the colon. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (eds): Textbook of Gastroenterology. Philadelphia, PA: Lippincott, 1991: 1645-1674.
6. Luk GD: Cancer surveillance strategies. In: Sleisenger MH, Fordtran JS, Scharschmidt BD, Feldman M (eds): Gastrointestinal disease. Orlando: W. B. Saunders, 1993: 115-126.
7. Luk GD, Arlow FL: Effects of calcium on polyamine metabolism and proliferation in colonocytes. In: Lipkin M, Newmark HL, Kelloff G (eds): Calcium, vitamin D and prevention of colon cancer. Boca Raton: CRC Press, 1991: 359-375.
8. Luk GD: Clinical and biologic studies of DFMO in the colon. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ (eds): Cancer chemoprevention. Boca Raton: CRC Press, 1992: 515-530.
9. Kelloff GJ, Boone CW, Steele VE, Crowel JA, Lubet R, Sigman CC: Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials. Cancer Res 1994; 54 (Suppl.): 2015S-2024S.
10. Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Sigman CC: Chemopreventive drug development: Perspectives and progress. Cancer Epidemiology, Biomarkers and Prevention 1994; 3: 85-98.
11. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
12. Turner D, Berkel HJ: Nonsteroidal anti-inflammatory drugs for the prevention of colon cancer. Can Med Assoc J 1993; 149: 595-602.
13. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
14. Meade EA, Smith WL, DeWitt DL: Expression of the murine prostaglandin (PGH) synthase-1 and PGH synthase-2 isozymes in cos-1 cells. J Lipid Mediat 1993; 6: 119-129.
15. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388.
16. O'Neill GP, Ford-Hutchinson AW: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letts 1993; 330: 156-160.
17. DeWitt DL: Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991; 1083: 121-134.
18. DeWitt DL, Meade EA, Smith WL: PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95 (Suppl. 2A): 40S-44S.
19. Craven PA, Neidig M, DeRubertis FR: Fatty acid-stimulated oxidation of methylazoxymethanol by rat colonic mucosa. Cancer Res 1985; 45: 1115-1121.
20. Wild D, Degan GH: Prostaglandin H synthetase-dependent mutagenic activity of heterocyclic aromatic amines of the IQ type. Carcinogenesis 1987; 8: 541-545.
21. Craven PA, DeRubertis FR: Effects of aspirin on 1,2-dimethylhydrazine-induced colonic Carcinogenesis. Carcinogenesis 1992; 13: 541-546.
22. Bennett A, Del Tacca M, Stamford IF, Zebro T: Prostaglandins from tumors of human large bowel. Br J Cancer 1977; 35: 881-884.
23. Blomgren H, Kling-Andersson G: Growth inhibition of human malignant glioma cells in vitro by agents which interfere with biosynthesis of eicosanoids. Anticancer Res 1992; 12: 981-986.
24. Cyran JA, Lysz TW, Lea MA: Influence of inhibitors of eicosanoid metabolism on proliferation of rat hepatoma cells and on tumor-host interaction. Prostaglandins Leukotrienes Essential Fatty Acids 1990; 39: 311-317.
25. Rose DP, Connolly JM: Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991; 18: 243-254.
26. Sato M, Narisawa T, Sano M, Takahashi T, Goto A: Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. J Cancer Res Clin Oncol 1983; 106: 21-26.
27. Fontan PA, Amura CR, Sordelli DO: Treatment with a nonsteroidal anti-inflammatory agent delays the growth of spontaneous pulmonary metastases of a mammary adenocarcinoma of non-detected immunogenicity. BrJ Cancer 1992; 66: 800-804.
28. Denizot Y, Najid A, Rigaud M: Effects of eicosanoid metabolism inhibitors on growth of a human gastric tumor cell line (HGT). Cancer Lett 1993; 73: 65-71.
29. Rose DP, Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 1990; 50: 7139-7144.
30. Bayer BM, Beaven MA: Evidence that indomethacin reversibly inhibits cell growth in the G1 phase of the cell cycle. Biochem Pharmacol 1979; 28: 441-443.
31. Bayer BM, Kruth HS, Vaughan M, Beaven MA: Arrest of cultured cells in the G1 phase of the cell cycle by indomethacin. J Pharmacol Exp Ther 1979; 210: 106-111.
32. Huang NN, Wang DJ, Gonzalez F, Heppel LA: Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation. J Cell Physiol 1991; 146: 483-494.
33. Yanagi S, Yamashita M, Hiasa Y: Aspirin shares a short-term effect, inhibition of pyruvate kinase activity with tumor-promoting agents, but fails to promote rat liver carcinogenesis. Oncology 1993; 50: 275-278.
34. Verma AK, Rice HM, Boutwell RK: Prostaglandins and skin tumor promotion: inhibition of tumor promoter-induced ornithine decarboxylase activity in epidermis by inhibitors of prostaglandin synthesis. Biochem Biophys Res Commun 1977; 79: 1160-1166.
35. Luk GD: Polyamines and colon cancer cells. In: Moyer MP, Poste GH (eds): Colon cancer cells. San Diego: Academic Press, 1990: 279-288.
36. Luk GD: Polyamines in normal and adaptive growth. In: Dowling RH, Folsch UR, Loser C (eds): Polyamines in the gastrointestinal tract. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1992: 205-216.
37. Moshier JA, Dosescu J, Skunca M, Luk GD: Transformation of NIH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res 1993; 53: 2618-2622.
38. Luk GD, Hamilton SR, Yang P, Smith JA, O'Ceallaigh D et al.: Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane-induced colonic carcinogenesis in the rat. Cancer Res 1986; 46: 4449-4452.
39. Zhang SZ, Luk GD, Hamilton SR: Alpha-difluoromethyl ornithine-induced inhibition of growth of autochthonous experimental colonic tumors produced by azoxymethane in male F344 rats. Cancer Res 1988; 48: 6498-6503.
40. Luk GD, Zhang SZ, Hamilton SR: Effects of timing of administration and dose of difluoromethylornithine on rat colonic carcinogenesis. JNCL 1989; 81: 421-427.
41. Wu KK, Sanduja R, Tsai A-L, Ferhanoglu B, Loose-Mitchell DS: Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci USA 1991; 88: 2384-2387.
42. Zyglewska T, Sanduja R, Ohashi K, Loose-Mitchell DS, Sanduja SK, Wu KK: Inhibition of endothelial cell prostaglandin H synthase gene expression by naproxen. Biochim Biophys Acta 1992; 1131: 78-82.
43. Singh J, Kelloff G, Reddy BS: Intermediate biomarkers of colon cancer: modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis 1993; 14: 699-704.
44. Goodwin JS: Immunologic effects of nonsteroidal anti-inflammatory drugs. Am J Med 1984; 77: 5-15.
45. Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295-315.
46. Stanojevic-Bakic N, Vuckovic-Dekic L, Susnjar S, Spuzic I: In vitro effect of indomethacin on mitogen-induced lymphoproliferative response in lung cancer patients. Neoplasma 1992; 39: 129-132.
47. Petrini B, Wolk G, Wasserman J, Vedin I, Strannegard O et al.: Indomethacin modulation of monocyte cytokine release following pelvic irradiation for cancer. Eur J Cancer 1991; 27: 591-594.
48. Lotzerich H, Japel M, Rogalla K: Influence of acetylsalicylic acid on antibody-dependent cellular cytotoxicity (ADCC) of peritoneal macrophages. Anticancer Res 1993; 13: 87-91.
49. Taffert SM, Russell SW: Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 1981; 126: 424-427.
50. Brunda MJ, Herberman RB, Holden HT: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980; 124: 2682-2687.
51. Blomgren H, Rotstein S, Wasserman J, Petrini B, Hammarstrom S: In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer. Radiother Oncol 1990; 19: 329-335.
52. Cross DS, Platt JL, Juhn SK, Bach FH, Adams GL: Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1992; 118: 526-528.
53. Han T, Nemoto T, Ledesma EJ, Bruno S: Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients. Int J Immunopharmacol 1983; 5: 11-15.
54. Pollard M, Luckert PH: Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323-1327.
55. Pollard M, Luckert PH: Treatment of chemically-induced intestinal cancer with indomethacin. Proc Soc Exp Biol Med 1981; 167: 161-164.
56. Kudo T, Narisawa T, Abo S: Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 1980; 71: 260-264.
57. Pollard M, Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumours in rats. J Natl Cancer Inst 1983; 70: 1103-1105.
58. Narisawa T, Hermanek P, Habs M, Schmahl D: Reduction of carcinogenicity of N-nitrosomethylurea by indomethacin and failure of resuming effect of prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 1984; 108: 239-242.
59. Metzger U, Meier J, Uhlschmid G et al.: Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984; 27: 366-369.
60. Narisawa T, Satoh M, Sano M et al.: Inhibition of development of methylnitrosourea-induced rat colon tumours by indomethacin treatment. Cancer Res 1981; 41: 1954-1957.
61. Narisawa T, Satoh M, Sano M et al.: Inhibition of initiation on promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983; 4: 1225-1227.
62. Pollard M, Luckert PH, Schmidt MA: The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 1983; 21: 57-61.
63. Pollard M, Luckert PH: Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosurea. Cancer Lett 1984: 25: 117-121.
64. Nigro ND, Bald AQ, Boyd ME: Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylorinithine with piroxicam or fish oil. J Natl Cancer Inst 1986; 77: 1309-1313.
65. Reddy BS, Maruyama H, Kelloff, G: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal inflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-5346.
66. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D, L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50; 2562-2568.
67. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991; 51: 4528-4534.
68. Reddy BS, Tokumo K, Kulkarni N, Aligia C, Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-1023.
69. Moorghen M, Ince P, Finney KJ, Sunter JP, Watson AJ, Appleton DR: The effect of sulindac on colonic tumour formation in dimethylhydrazine-treated mice. Acta Histochem 1990; 39: 195-199.
70. Skinner SA, Penney AG, O'Brien PE: Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991; 126: 1094-1096.
71. Pepin P, Bouchard L, Nicole P, Castonguay A: Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis 1992; 13: 341-348.
72. Lala PK, Parhar RS: Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int J Cancer 1993; 54: 677-684.
73. Jalbert G, Castonguay A: Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett 1992; 66: 21-28.
74. Mehta RG, Steele V, Kelloff GJ, Moon RC: Influence of thiols and inhibitors of prostaglandin biosynthesis on the carcinogen-induced development of mammary lesions in vitro. Anticancer Res 1991; 11: 587-591.
75. Noguchi M, Taniya T, Koyasaki N, Kumaki T, Miyazaki I, Mizukami Y: Effects of the prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 1991; 51: 2683-2689.
76. Klan R, Knispel HH, Meier T: Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl)nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol 1993; 119: 482-485.
77. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC: Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 1993; 14: 1487-1489.
78. Valdez JC, Perdigon G: Piroxicam, indomethacin and aspirin action on a murine fibrosarcoma. Effects on tumour-associated and peritoneal macrophages. Clin Exp Immunol 1991; 86: 315-321.
79. Knapp DW, Richardson RC, Bottoms GD, Teclaw R, Chan TC: Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992; 29: 214-218.
80. Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-523.
81. Goerttler K, Edler L, Loehrke H: Long term tumorigenicity of a single application of indomethacin or Amuno in adolescent and in adult male Sprague Dawley rats. Exp Toxicol Pathol 1992; 44: 361-370.
82. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-1497.
83. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne colorectal cancer study. Cancer Res 1988; 48: 4399-4004.
84. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358.
85. Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst 1991; 83: 1182-1183.
86. Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin and reduced risk of fatal colon cancer [Letter]. N Engl J Med 1992; 326: 1290.
87. Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247-1250.
88. Thun MJ, Namboodiri MM, Health CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-1596.
89. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr: Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
90. Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171-1177.
91. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-146.
92. Satterfield S, Greco PJ, Goldhaber SZ, Stampfer MJ, Swartz SL et al.: Biochemical markers of compliance in the Physicians' Health Study. Am J Prev Med 1990; 6: 290-294.
93. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-135.
94. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-1224.
95. Gridley G, McLaughlin JK, Ekbom A et al.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307-311.
96. Logan RF, Little J, Hawtin PG, Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. Br Med J 1993; 307: 285-289.
97. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R: Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993; 85: 912-916.
98. Pelig I, Maibach HT, Wilcox CM: Aspirin (ASA), NSAID use and the risk of subsequent colorectal polyps. Gastroenterology 1993; 104: A440.
99. Peleg I, Cotsonis GA, Wilcox CM: Nonsteroidal anti-inflammatory drug, acetaminophen, calcium, psyllium, and multivitamin use and the risk of subsequent colorectal adenomas. Gastroenterology 1994; 106: A426.
100. Wishingrad M, Titzer D, Triadafilopoulos G, Omary B: Chronic aspirin and NSAID use may protect against colorectal adenomas. Gastroenterology 1994; 106: A451.
101. Waddell WR, Loughry RW: Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-87.
102. Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179.
103. Rigau J, Pique JM, Rubio E, Planas R, Tarrech JM, Bordas JM: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-954.
104. Iwama T, Imajo M, Mishima Y: Is sulindac effective for familial adenomatosis polyposis? [Letter] Int J Colorect Dis 1991; 6: 235.
105. Tonelli F, Valanzano R: Sulindac in familial adenomatous polyposis [Letter]. Lancet 1993; 342: 1120.
106. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639.
107. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
108. Feinberg SM, Jagelman DG, Sarre RG, McGannon E, Fazio VW et al.: Spontaneous resolution of rectal polyps in patients with familial adenomatous polyposis following abdominal colectomy and ileorectal anastomosis. Dis Colon Rectum 1988; 31: 169-175.
109. Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R et al.: Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-366.
110. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS: Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-1619.
111. Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H: The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993; 8: 13-17.
112. Parker AL, Kadakia SC, Maccini DM, Cassaday MA, Angueira CE: Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993; 88: 93-94.
113. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE: NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993; 88: 1652-1656.
114. Aabakken L: Review article: Non-sterpidal, anti-inflammatory drugs - extending scope of gastrointestinal side effects. Aliment Pharmacol Ther 1992; 6: 143-162.
115. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219-226.
116. Gibson GR, Whitacre EB, Ricotti CA: Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992; 152: 625-632.
117. Dubach UC, Rosner B, Sturmer T: An epidemiologic study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N Engl J Med 1991; 324: 155-160.
118. Shorrock CJ, Langman MJS, Warlow C: Risk of upper GI bleeding during TIA prophylaxis with aspirin. Gastroenterology 1992; 103: A165.
119. Hawkey CJ: Nonsteroidal anti-inflammatory drugs and peptic ulcers. Br Med J 1990; 300: 278-284.
120. Hawkey CJ: Review article: Aspirin and gastrointestinal bleeding. Aliment Pharmacol Ther 1994; 8: 141-146.
121. Alino SF, Unda FJ, Iruarrizaga A, Alfaro J, Hilario E et al.: Efficacy of liposome-encapsulated indomethacin in response against metastatic 3LL and B16F1 tumor cells. Lab Invest 1992; 66: 671-679.
122. Alino SF, Iruarrizaga A, Alfaro J, Almena A, Lejarreta M, Unda FJ: Antimetastatic effects of liposome entrapped indomethacin. Life Sci 1991; 48: 149-154.
123. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-6614.
124. Servais P, Taton G, Galand P: Modulation by indomethacin of diethylnitrosamine-induced early changes in c-myc and c-ras expression and late incidence of preneoplastic lesions in rat liver. Carcinogenesis 1990; 11: 1433-1436.
125. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-7244.